Publication:
Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells

dc.contributor.authorÇoker Gürkan, Ajda
dc.contributor.authorPalavan Unsal, Narçin
dc.contributor.authorARISAN, ELİF DAMLA
dc.contributor.authorYERLİKAYA, PINAR OBAKAN
dc.contributor.authorKILBAŞ, PELİN ÖZFİLİZ
dc.contributor.authorID156421tr_TR
dc.contributor.authorID113920tr_TR
dc.contributor.authorID195744tr_TR
dc.contributor.authorID125860tr_TR
dc.contributor.authorID6125tr_TR
dc.date.accessioned2018-07-13T06:59:10Z
dc.date.available2018-07-13T06:59:10Z
dc.date.issued2014
dc.description.abstractPurvalanol A is a specific CDK inhibitor which triggers apoptosis by causing cell cycle arrest in cancer cells. Although it has strong apoptotic potential, the mechanistic action of Purvalanol A on significant cell signaling targets has not been clarified yet. Polyamines are crucial metabolic regulators affected by CDK inhibition because of their role in cell cycle progress as well. In addition, malignant cells possess impaired polyamine homeostasis with high level of intracellular polyamines. Especially induction of polyamine catabolic enzymes spermidine/spermine N1-acetyltransferase (SSAT), polyamine oxidase (PAO) and spermine oxidase (SMO) induced toxic by-products in correlation with the induction of apoptosis in cancer cells. In this study, we showed that Purvalanol A induced apoptosis in caspase- dependent manner in MCF-7 ER(+) cells, while MDA-MB-231 (ER-) cells were less sensitive against drug. In addition Bcl-2 is a critical target for Purvalanol A, since Bcl-2 overexpressed cells are more resistant to Purvalanol A-mediated apoptosis. Furthermore, exposure of MCF-7 cells to Purvalanol A triggered SSAT and PAO upregulation and the presence of PAO/SMO inhibitor, MDL 72,527 prevented Purvalanol A-induced apoptosis.tr_TR
dc.identifier.issn0301-4851
dc.identifier.pubmed24190492
dc.identifier.pubmed24190492en
dc.identifier.scopus2-s2.0-84891928290
dc.identifier.scopus2-s2.0-84891928290en
dc.identifier.urihttps://doi.org/10.1007/s11033-013-2847-1
dc.identifier.urihttps://hdl.handle.net/11413/2063
dc.identifier.wos329100500018
dc.identifier.wos329100500018en
dc.language.isoen_UStr_TR
dc.publisherSpringer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlandstr_TR
dc.relationMolecular Biology Reportstr_TR
dc.subjectPolyaminestr_TR
dc.subjectApoptosistr_TR
dc.subjectPurvalanol Atr_TR
dc.subjectBreast cancertr_TR
dc.subjectBcl-2tr_TR
dc.subjectDown-Regulationtr_TR
dc.subjectRoscovitinetr_TR
dc.subjectInhibitorstr_TR
dc.subjectAgentstr_TR
dc.subjectPhosphorylationtr_TR
dc.subjectTherapeuticstr_TR
dc.subjectCaspase-3tr_TR
dc.subjectSperminetr_TR
dc.subjectDiseasetr_TR
dc.subjectOxidasetr_TR
dc.titlePurvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cellstr_TR
dc.typeArticle
dspace.entity.typePublication
local.indexed.atpubmed
local.indexed.atscopus
local.indexed.atwos
relation.isAuthorOfPublication3d33e154-a50c-46b8-ad6e-25a26bf11cf0
relation.isAuthorOfPublication387670e2-5a88-4937-b3da-1dda9aedfbdd
relation.isAuthorOfPublicationa500c512-a91e-4d19-bab8-804faf6648a8
relation.isAuthorOfPublication.latestForDiscovery3d33e154-a50c-46b8-ad6e-25a26bf11cf0

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: